

Chelsea C Pinnix

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9087698/publications.pdf>

Version: 2024-02-01

135
papers

2,532
citations

218592

26
h-index

223716

46
g-index

138
all docs

138
docs citations

138
times ranked

3386
citing authors

#	ARTICLE	IF	CITATIONS
1	Double hit lymphoma: the <scp>MD Anderson </scp> cancer <scp>Center </scp> clinical experience. <i>British Journal of Haematology</i> , 2014, 166, 891-901.	1.2	310
2	Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 2871-2883.	2.5	134
3	Predictors of Radiation Pneumonitis in Patients Receiving Intensity Modulated Radiation Therapy for Hodgkin and Non-Hodgkin Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 175-182.	0.4	110
4	Dosimetric advantages of a "butterfly" technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin's lymphoma. <i>Radiation Oncology</i> , 2014, 9, 94.	1.2	90
5	Ultra"low" dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. <i>Head and Neck</i> , 2017, 39, 1095-1100.	0.9	87
6	Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation. <i>Blood</i> , 2018, 131, 84-94.	0.6	78
7	Cardiac atlas development and validation for automatic segmentation of cardiac substructures. <i>Radiotherapy and Oncology</i> , 2017, 122, 66-71.	0.3	76
8	Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 652-669.	0.4	71
9	Involved Site Radiation Therapy in Adult Lymphomas: An Overview of International Lymphoma Radiation Oncology Group Guidelines. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 909-933.	0.4	67
10	Topical Hyaluronic Acid vs. Standard of Care for the Prevention of Radiation Dermatitis After Adjuvant Radiotherapy for Breast Cancer: Single-Blind Randomized Phase III Clinical Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 1089-1094.	0.4	65
11	Encouraging activity for R-CHOP in advanced stage nodular lymphocyte"predominant Hodgkin lymphoma. <i>Blood</i> , 2017, 130, 472-477.	0.6	65
12	A PET Radiomics Model to Predict Refractory Mediastinal Hodgkin Lymphoma. <i>Scientific Reports</i> , 2019, 9, 1322.	1.6	62
13	Characteristics, management, and outcomes of patients with follicular dendritic cell sarcoma. <i>British Journal of Haematology</i> , 2017, 178, 403-412.	1.2	57
14	Single-Institution Experience in the Treatment of Primary Mediastinal B Cell Lymphoma Treated With Immunochemotherapy in the Setting of Response Assessment by 18Fluorodeoxyglucose Positron Emission Tomography. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 113-121.	0.4	50
15	Whole Abdominopelvic Intensity-Modulated Radiation Therapy for Desmoplastic Small Round Cell Tumor After Surgery. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 317-326.	0.4	48
16	Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. <i>Cancer</i> , 2016, 122, 2680-2688.	2.0	48
17	Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1914-1920.	2.0	46
18	Myelopathy following intrathecal chemotherapy in adults: a single institution experience. <i>Journal of Neuro-Oncology</i> , 2015, 122, 391-398.	1.4	40

#	ARTICLE	IF	CITATIONS
19	Radiation in Central Nervous System Leukemia: Guidelines From the International Lymphoma Radiation Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 53-58.	0.4	39
20	Pre-treatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2018, 180, 545-549.	1.2	38
21	Benefit of Consolidative Radiation Therapy for Primary Bone Diffuse Large B-Cell Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 122-129.	0.4	37
22	Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy. <i>JAMA Oncology</i> , 2016, 2, 1065.	3.4	36
23	Primary cutaneous B-cell lymphoma (non-leg type) has excellent outcomes even after very low dose radiation as single-modality therapy. <i>Leukemia and Lymphoma</i> , 2016, 57, 34-38.	0.6	34
24	Outcomes After Reduced-Dose Intensity Modulated Radiation Therapy for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 447-455.	0.4	31
25	Dorsal column myelopathy after intrathecal chemotherapy for leukemia. <i>American Journal of Hematology</i> , 2017, 92, 155-160.	2.0	30
26	Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG. <i>Blood</i> , 2020, 135, 2365-2374.	0.6	30
27	Coronary Artery Dose-Volume Parameters Predict Risk of Calcification After Radiation Therapy. <i>Journal of Cardiovascular Imaging</i> , 2019, 27, 268.	0.2	30
28	The Management of Lymphoma in the Setting of Pregnancy. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 251-256.	1.2	29
29	Intensive chemoimmunotherapy and bilateral globe irradiation as initial therapy for primary intraocular lymphoma. <i>Neuro-Oncology</i> , 2016, 18, 575-581.	0.6	24
30	Predictors of Hypothyroidism in Hodgkin Lymphoma Survivors After Intensity Modulated Versus 3-Dimensional Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 530-540.	0.4	23
31	Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCL. <i>Blood Advances</i> , 2018, 2, 1334-1343.	2.5	23
32	Comprehensive Craniospinal Radiation for Controlling Central Nervous System Leukemia. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 1119-1125.	0.4	22
33	Craniospinal irradiation prior to stem cell transplant for hematologic malignancies with CNS involvement: Effectiveness and toxicity after photon or proton treatment. <i>Practical Radiation Oncology</i> , 2017, 7, e401-e408.	1.1	21
34	Radiation Therapy Is an Effective Modality in the Treatment of Mantle Cell Lymphoma, Even in Heavily Pretreated Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 474-479.	0.2	20
35	Radiation and CAR T-cell Therapy in Lymphoma: Future Frontiers and Potential Opportunities for Synergy. <i>Frontiers in Oncology</i> , 2021, 11, 648655.	1.3	19
36	Radiation-related heart and vascular disease. <i>Future Oncology</i> , 2015, 11, 2067-2076.	1.1	18

#	ARTICLE	IF	CITATIONS
37	A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation. <i>Cancer</i> , 2017, 123, 1363-1371.	2.0	18
38	Linguistic Biases in Letters of Recommendation for Radiation Oncology Residency Applicants from 2015 to 2019. <i>Journal of Cancer Education</i> , 2022, 37, 965-972.	0.6	18
39	An international multicenter retrospective analysis of patients with extranodal marginal zone lymphoma and histologically confirmed central nervous system and dural involvement. <i>Cancer Medicine</i> , 2020, 9, 663-670.	1.3	17
40	Radiation therapy related cardiac disease risk in childhood cancer survivors: Updated dosimetry analysis from the Childhood Cancer Survivor Study. <i>Radiotherapy and Oncology</i> , 2021, 163, 199-208.	0.3	17
41	Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration. <i>American Journal of Hematology</i> , 2016, 91, 894-899.	2.0	15
42	Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1602-1609.	2.0	15
43	Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1146-1154.	0.4	15
44	Breast Implant-associated Anaplastic Large Cell Lymphoma. <i>Annals of Surgery</i> , 2022, 275, e245-e249.	2.1	15
45	Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma. <i>Haematologica</i> , 2022, 107, 1555-1566.	1.7	15
46	Radiation therapy for salivary gland MALT lymphoma: ultra-low dose treatment achieves encouraging early outcomes and spares salivary function. <i>Leukemia and Lymphoma</i> , 2020, 61, 171-175.	0.6	14
47	Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 2833-2844.	0.6	13
48	Daily CT guidance improves target coverage during definitive radiation therapy for gastric MALT lymphoma. <i>Practical Radiation Oncology</i> , 2017, 7, e471-e478.	1.1	13
49	Deep-Inspiration Breath-Hold Intensity Modulated Radiation Therapy to the Mediastinum for Lymphoma Patients: Setup Uncertainties and Margins. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 254-262.	0.4	13
50	Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 122-128.	0.2	12
51	Primary breast diffuse large B-cell lymphoma: treatment strategies and patterns of failure. <i>Leukemia and Lymphoma</i> , 2018, 59, 2896-2903.	0.6	12
52	Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma. <i>Blood Advances</i> , 2019, 3, 1356-1367.	2.5	12
53	Emerging Treatment Strategies for Primary Breast Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 244-250.	0.2	11
54	Effect of Deep Inspiration Breath Hold on Normal Tissue Sparing With Intensity Modulated Radiation Therapy Versus Proton Therapy for Mediastinal Lymphoma. <i>Advances in Radiation Oncology</i> , 2020, 5, 1255-1266.	0.6	11

#	ARTICLE	IF	CITATIONS
55	Development, implementation, and outcomes of a simulation-based medical education (SBME) prostate brachytherapy workshop for radiation oncology residents. <i>Brachytherapy</i> , 2020, 19, 738-745.	0.2	11
56	Chemotherapy Response Assessment by FDG-PET-CT in Early-stage Classical Hodgkin Lymphoma: Moving Beyond the Five-Point Deauville Score. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 333-338.	0.4	10
57	Decreased heart dose with deep inspiration breath hold for the treatment of gastric lymphoma with IMRT. <i>Clinical and Translational Radiation Oncology</i> , 2020, 24, 79-82.	0.9	10
58	New paradigm for radiation in multiple myeloma: lower yet effective dose to avoid radiation toxicity. <i>Haematologica</i> , 2020, 105, e355-e357.	1.7	10
59	Treatment of Early-Stage Unfavorable Hodgkin Lymphoma: Efficacy and Toxicity of 4 Versus 6 Cycles of ABVD Chemotherapy With Radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 110-118.	0.4	9
60	Effectiveness of low-dose radiation for primary cutaneous anaplastic large cell lymphoma. <i>Advances in Radiation Oncology</i> , 2017, 2, 363-369.	0.6	9
61	Early-stage Hodgkin lymphoma outcomes after combined modality therapy according to the post-chemotherapy 5-point score: can residual pet-positive disease be cured with radiotherapy alone?. <i>British Journal of Haematology</i> , 2017, 179, 488-496.	1.2	9
62	Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy. <i>Advances in Radiation Oncology</i> , 2018, 3, 639-646.	0.6	9
63	Outcome of relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: a North American analysis. <i>British Journal of Haematology</i> , 2021, 192, 560-567.	1.2	9
64	Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation Therapy. <i>JAMA Network Open</i> , 2020, 3, e2013935.	2.8	8
65	Postoperative Radiotherapy for Multiple Myeloma of Long Bones: Should the Entire Rod Be Treated?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e465-e469.	0.2	7
66	Frontline antibiotic therapy for early-stage <i>Helicobacter pylori</i> -negative gastric MALT lymphoma. <i>American Journal of Hematology</i> , 2019, 94, E150-E153.	2.0	7
67	Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e51-e61.	0.2	7
68	Development and validation of an age-scalable cardiac model with substructures for dosimetry in late-effects studies of childhood cancer survivors. <i>Radiotherapy and Oncology</i> , 2020, 153, 163-171.	0.3	7
69	Does Bleomycin Lung Toxicity Increase the Risk of Radiation Pneumonitis in Hodgkin Lymphoma?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 951-958.	0.4	6
70	Radiation Therapy for Diffuse Large B-Cell Lymphoma: Indications, Outcomes, and Controversies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 641-644.	0.4	6
71	Using benchmarked lung radiation dose constraints to predict pneumonitis risk: Developing a nomogram for patients with mediastinal lymphoma. <i>Advances in Radiation Oncology</i> , 2018, 3, 372-381.	0.6	6
72	Multi-institutional Investigation: Circulating CD4:CD8 ratio is a prognosticator of response to total skin electron beam radiation in mycosis fungoides. <i>Radiotherapy and Oncology</i> , 2019, 131, 88-92.	0.3	6

#	ARTICLE	IF	CITATIONS
73	Prevalence of a Histologic Change of Ocular Adnexal Lymphoma in Patients With a History of Lymphoma. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2019, 35, 243-246.	0.4	6
74	Primary Mediastinal B Cell Lymphoma in the Positron-Emission Tomography Era Executive Summary of the American Radium Society Appropriate Use Criteria. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 36-44.	0.4	6
75	Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 1609-1609.	0.6	6
76	Diffuse large B-cell lymphoma in very elderly patients over 80 years old: Incorporating consolidative radiation therapy into management decisions. <i>Advances in Radiation Oncology</i> , 2017, 2, 370-380.	0.6	5
77	Partial omission of bleomycin for early-stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?. <i>EJHaem</i> , 2020, 1, 272-276.	0.4	5
78	Potential Implications of the New USMLE Step 1 Pass/Fail Format for Diversity Within Radiation Oncology. <i>Advances in Radiation Oncology</i> , 2021, 6, 100524.	0.6	5
79	A Prospective Trial of Radiation Therapy Efficacy and Toxicity for Localized Mucosa-associated Lymphoid Tissue (MALT) Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1414-1420.	0.4	5
80	Double Hit Lymphoma: M.D. Anderson Experience. <i>Blood</i> , 2013, 122, 1776-1776.	0.6	5
81	High Risk Diffuse Large B Cell Lymphoma: A Comparison of Aggressive Subtypes Treated with Dose Adjusted Chemotherapy-the University of Texas MD Anderson Experience. <i>Blood</i> , 2016, 128, 106-106.	0.6	5
82	Outcomes After Chemotherapy Followed by Radiation for Stage IIB Hodgkin Lymphoma With Bulky Disease. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 664-670.e2.	0.2	4
83	PET Guided Therapy for Early Stage Hodgkin Lymphoma: Are We Positive About a Negative Interim Scan?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 12-17.	0.4	4
84	Nodular lymphocyte predominant Hodgkin lymphoma: executive summary of the American radium society appropriate use criteria. <i>Leukemia and Lymphoma</i> , 2021, 62, 1057-1065.	0.6	4
85	The impact of cell-of-origin, MYC/Bcl-2 dual expression and <i>MYC</i> rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy. <i>Leukemia and Lymphoma</i> , 2021, 62, 1361-1369.	0.6	4
86	Report from the SWOG Radiation Oncology Committee: Research Objectives Workshop 2017. <i>Clinical Cancer Research</i> , 2018, 24, 3500-3509.	3.2	3
87	Early Stage Extranodal Follicular Lymphoma: Characteristics, Management, and Outcomes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 381-389.	0.2	3
88	Ibrutinib-based therapy for the treatment of marginal zone lymphoma with central nervous system involvement. <i>Leukemia and Lymphoma</i> , 2020, 61, 2980-2984.	0.6	3
89	Daily computed tomography image guidance: Dosimetric advantages outweigh low-dose radiation exposure for treatment of mediastinal lymphoma. <i>Radiotherapy and Oncology</i> , 2020, 152, 14-18.	0.3	3
90	Serum paraprotein persistence and size determine outcome in a cohort of patients with a modern definition of plasmacytoma with up to 19 years of follow up. <i>Blood Cancer Journal</i> , 2021, 11, 17.	2.8	3

#	ARTICLE	IF	CITATIONS
91	Graft-versus-host disease after radiation therapy in patients who have undergone allogeneic stem cell transplantation: two case reports. <i>Journal of Medical Case Reports</i> , 2016, 10, 209.	0.4	2
92	Omitting cardiophrenic lymph nodes in the treatment of patients with Hodgkin lymphoma via modified involved-site radiation therapy. <i>Leukemia and Lymphoma</i> , 2018, 59, 2650-2659.	0.6	2
93	Coincident primary breast lymphoma and gastrointestinal stromal tumor: case series and molecular mechanisms. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 8937-8942.	1.0	2
94	Limited stage grade 3 follicular lymphoma patients can experience favorable outcomes with combined modality therapy. <i>Leukemia and Lymphoma</i> , 2019, 60, 2432-2440.	0.6	2
95	Imaging Surveillance of Limited-stage Classic Hodgkin Lymphoma Patients After PET-CT-documented First Remission. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 533-541.	0.2	2
96	Salvage radiotherapy for primary refractory and relapsed diffuse large B-Cell lymphoma. <i>British Journal of Radiology</i> , 2021, 94, 20210360.	1.0	2
97	Potential Impact of Consolidation Radiation Therapy for Advanced Hodgkin Lymphoma: A Secondary Modeling of SWOG S0816 with Receiver Operating Characteristic Analysis. <i>Blood</i> , 2018, 132, 2927-2927.	0.6	2
98	Gastric MALT Lymphoma Treated With Primary Radiotherapy in the Setting of Autoimmune Disease. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 815-819.	2.3	2
99	Assessment of Lymphoma and Other Hematologic Malignancies Training Needs Among Radiation Oncology Residents: a Brief Report. <i>Journal of Cancer Education</i> , 2023, 38, 201-205.	0.6	2
100	Prognostic significance of EGFR and KRAS mutations in NSCLC patients with brain metastases treated with radiosurgery. <i>Journal of Radiosurgery and SBRT</i> , 2015, 3, 171-178.	0.2	2
101	Incidence and predictors of Lhermitte's sign among patients receiving mediastinal radiation for lymphoma. <i>Radiation Oncology</i> , 2015, 10, 206.	1.2	1
102	Small Lymphocytic Lymphoma Presenting with Hypopituitarism. <i>American Journal of Medicine</i> , 2016, 129, e9-e10.	0.6	1
103	Acute and late toxicity of bilateral orbital irradiation in the management of primary intraocular lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 2612-2618.	0.6	1
104	Lymphoma and Pregnancy—Reply. <i>JAMA Oncology</i> , 2017, 3, 567.	3.4	1
105	Radiotherapy in Patients with Mycosis Fungoides and Central Nervous System Involvement. <i>Case Reports in Oncology</i> , 2018, 11, 721-728.	0.3	1
106	Additional therapy improves outcomes in completely resected, limited-stage follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 3258-3265.	0.6	1
107	The Role of Radiation Therapy in Hematopoietic Stem Cell Transplantation. , 2019, , 59-72.		1
108	Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816. <i>Leukemia and Lymphoma</i> , 2020, 61, 2442-2447.	0.6	1

#	ARTICLE	IF	CITATIONS
109	Prognostic value of disease distribution in secondary central nervous system diffuse large B cell lymphoma treated with radiation therapy. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-8.	0.6	1
110	Prospective Phase 2 Trial of High-Dose Gemcitabine/Busulfan/Melphalan (Gem/Bu/Mel) with Autologous Stem-Cell Transplant (ASCT) without Post-ASCT Maintenance, in Hodgkins Lymphoma Patients at High Risk of Post-Transplant Recurrence Comparison with a Concurrent Matched Cohort Treated with BEAM. <i>Blood</i> , 2015, 126, 1980-1980.	0.6	1
111	Analyzing Patient Characteristics Who Received (DA) EPOCH-R for High Risk Diffuse Large B-Cell Lymphoma: MD Anderson Cancer Center Experience. <i>Blood</i> , 2016, 128, 4208-4208.	0.6	1
112	The Easix (Endothelial Activation and Stress Index) Score Predicts for CAR T Related Toxicity in Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2020, 136, 17-18.	0.6	1
113	Association of Vitamin D Deficiency with Inferior Treatment Outcomes in Patients with Newly Diagnosed Classic Hodgkin Lymphoma: MD Anderson Cancer Center Experience. <i>Blood</i> , 2020, 136, 27-28.	0.6	1
114	Implementation and Assessment of an Informal Virtual Elective for Medical Student Radiation Oncology Exploration During the COVID19 Pandemic: a Brief Report. <i>Journal of Cancer Education</i> , 2023, 38, 344-348.	0.6	1
115	Avoiding Topical Agents Before Daily Radiotherapy. <i>JAMA Oncology</i> , 2018, 4, 1748.	3.4	0
116	Rainbow IMRT and Volumetric Imaging for Anterior Mesenteric Targets. <i>Practical Radiation Oncology</i> , 2019, 9, 147-152.	1.1	0
117	Postâ€œscp>ABVD</scp> biopsy results, and not postâ€œscp>ABVD FDG</scp>â€œscp>PET</scp> results, predict outcome in earlyâ€œstage Hodgkin lymphoma: response to Adams and Kwee. <i>British Journal of Haematology</i> , 2019, 184, 292-293.	1.2	0
118	A call for an unbalanced force to combat racism and health disparity. <i>Lancet Haematology</i> , the, 2021, 8, e173-e174.	2.2	0
119	Treatment outcomes and prognostic factors for primary mediastinal B-cell lymphoma: The MD Anderson experience.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8564-8564.	0.8	0
120	Clinical Characteristics and Outcomes of Patients with Hodgkin Lymphoma with Central Nervous System Involvement: An International Multicenter Collaboration. <i>Blood</i> , 2015, 126, 3865-3865.	0.6	0
121	Radiation Pneumonitis Risk after Bleomycin Toxicity in Hodgkin Lymphoma Patients. <i>Blood</i> , 2015, 126, 1511-1511.	0.6	0
122	High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) with Consolidative Radiation Therapy (RT) for Relapsed or Refractory (R/R) Primary Mediastinal B-Cell Lymphoma (PMBCL): 20-Year Experience at MD Anderson Cancer Center (MDACC). <i>Blood</i> , 2020, 136, 32-33.	0.6	0
123	Long Term Outcome Patterns and Risk Factors for Early Mortality and Disease Progression in ALK-Positive Anaplastic Large Cell Lymphoma. <i>Blood</i> , 2021, 138, 2463-2463.	0.6	0
124	Outcomes of Patients with Extranodal Natural Killer/T-Cell Lymphoma: Single Institution Series. <i>Blood</i> , 2021, 138, 4536-4536.	0.6	0
125	Phase II Trial of Response Adapted Ultra Low Dose (ULD) Orbital Radiation Therapy for Indolent B Cell Lymphoma. <i>Blood</i> , 2021, 138, 3526-3526.	0.6	0
126	Radiomic Phenotypes of High and Low Lesion SUV Components for the Prediction of Refractory Disease in Hodgkin's Lymphoma Patients Treated with ABVD Based Therapy. <i>Blood</i> , 2021, 138, 3996-3996.	0.6	0

#	ARTICLE	IF	CITATIONS
127	Chemoradiation to Improve Local Control, and Thereby Overall Survival for Limited Stage Nasal NKTCL. International Journal of Radiation Oncology Biology Physics, 2021, 111, 1105-1106.	0.4	0
128	Association of Epstein-Barr Virus with Advanced Stage and Survival Outcomes in Classic Hodgkin's Lymphoma. Blood, 2020, 136, 37-38.	0.6	0
129	Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma. Blood, 2020, 136, 22-22.	0.6	0
130	Factors Associated with the Improvement of Outcomes of High-Risk Relapsed Hodgkin Lymphoma (HL) Patients Receiving High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT): The MD Anderson Cancer Center Experience. Blood, 2020, 136, 17-18.	0.6	0
131	Association of Smoking with Advanced Stage and Survival Outcomes in Classic Hodgkin's Lymphoma. Blood, 2020, 136, 34-35.	0.6	0
132	Brentuximab Vedotin with Chemotherapy in Frontline Treatment of Classic Hodgkin Lymphoma Nodular Sclerosis Syncytial Variant. Blood, 2020, 136, 28-29.	0.6	0
133	Retrospective Review of Prognostic and Predictors Markers in Newly Diagnosed Angioimmunoblastic T Cell Lymphoma at UT MD Anderson Cancer Center. Blood, 2020, 136, 27-28.	0.6	0
134	Prognostic Value of Delta Lymphocyte Index (DLI _x) in Patients with Large B-Cell Lymphoma (LBCL) Treated with Chimeric Antigen Receptor (CAR) T-Cell Therapy. Blood, 2020, 136, 23-24.	0.6	0
135	Real Life Treatment Alterations of Frontline Therapies in Classic Hodgkin's Lymphoma. Blood, 2020, 136, 23-24.	0.6	0